arrow
A

Annamaria Tomasso

Catholic University of Sacred Heart
H指数:7
被引数:132

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12

cBTKi治疗后无淋巴细胞增多是一种罕见现象,除主要表达于12号染色体三体性的CD49d阳性CLL外。

2026-04-070
OAAI
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice

重新思考维奈克拉-奥滨尤妥珠单抗在慢性淋巴细胞白血病中的可行性与安全性:非传统因素可能在临床实践中发挥作用

2026-01-014
OA
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study

家族性慢性淋巴细胞白血病比散发性形式的预后更差:一项意大利病例对照研究

2025-06-140
OAAI
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience
2025-01-140
OAAI
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience
2024-11-280
OAAI
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

家族性与散发性慢性淋巴细胞白血病的比较:一项意大利多中心病例对照研究

BLOOD
IF23.1
2024-11-050
PRE
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

在FCR治疗的慢性淋巴细胞白血病的真实多中心队列中,IGHV突变患者的长期益处

2022-10-103
PRE
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
2022-07-053
OAAI
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
2022-02-2416
OAAI
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics

慢性淋巴细胞白血病的皮下免疫球蛋白与二级抗体缺乏症。新型冠状病毒肺炎大流行期间的单中心经历

2022-02-024
OA